{
  "id": 12393980,
  "title": "Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?",
  "url": "https://urgent.news/2026/10/06/eli-lilly-and-vs-novo-nordisk-a-s-which-healthcare-stock-is-a-better",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-06T13:10:01.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/coverage/better-buy/2026/10/06/eli-lilly-and-vs-novo-nordisk-as-which-healthcare-stock-is-a-better-buy-in-2026/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "In the intense competition for supremacy in weight-loss and diabetes treatments, investors are faced with a significant decision in 2026 - should they invest in Eli Lilly (NYSE:LLY) or Novo Nordisk A/S (NYSE:NVO)? Both companies are currently capitalizing on the massive demand for GLP-1 medications, positioning themselves as the leading contenders in the modern healthcare landscape.\n\nEli Lilly, a global leader in human pharmaceuticals, focuses on high-growth areas such as oncology and immunology. The company's diverse portfolio in the U.S. is complemented by its rapid expansion into metabolic health. However, its customer concentration poses a risk, as three major wholesale distributors - McKesson (NYSE:MCK), Cencora (NYSE:COR), and Cardinal Health (NYSE:CAH) - handle a significant share of its distribution and product logistics.\n\nNovo Nordisk, on the other hand, remains a global powerhouse in insulin and obesity care. With decades of specialized expertise, this Danish company has established itself as a key player in the industry. As both companies take advantage of the soaring demand for GLP-1 medications, investors must carefully weigh the strengths and weaknesses of each company before making their investment decision in 2026.",
  "summary": "Eli Lilly's revenue surged 44.7% in 2025, but Novo Nordisk trades at less than a quarter of its valuation multiple, a stark contrast that reshapes the risk-reward calculus.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?",
        "url": "https://urgent.news/2026/10/06/eli-lilly-and-vs-novo-nordisk-a-s-which-healthcare-stock-is-a-better-12394928",
        "published": "2026-10-06T13:30:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}